AI and scans to predict immunotherapy response in liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated for liver cancer (hepatocellular carcinoma) at Wuhan Union Hospital between July 2025 and July 2026
- You are 18 years old or older
- You had at least one CT or MRI scan before starting treatment
- A tissue biopsy confirmed your diagnosis of liver cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an artificial intelligence system can help doctors find and treat liver cancer if it comes back after your first surgery or ablation. It focuses on early detection and providing another curative treatment if a recurrence is found.
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial uses a computer program to help doctors find signs of microscopic tumor spread in blood vessels (microvascular invasion) from liver cancer images. It aims to improve treatment planning for patients who are having surgery.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.